Accuragen accuragen.com


Public list: Digital Health (6428) Genomics (614)

Accuragen has developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in minuscule concentrations of circulating cell-free DNA (cfDNA) in blood. The Company's technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining proprietary techniques in molecular biology and computational algorithm for error suppression. With Accuragen's technology, nanogram quantities of highly-fragmented cfDN...Show all

Accuragen has developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in minuscule concentrations of circulating cell-free DNA (cfDNA) in blood. The Company's technology addresses the significant bar...Show all

Company (Alive / Active)

Phone: 650-618-5028

Fax:

1455 Adams Drive
Suite 1015
Menlo Park, 94025
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Accuragen $46.9M Jun 1, 2016
See all 6 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Accuragen Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 9 investors

Board Members

Competitors

Company Status Description Investors

20/20 GeneSystems

Rockville, Maryland, United States
Alive / Active20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a proprietary algorithm to combine the biomarker values to generate a unitary risk score.Login to see details

Biocept

San Diego, California, United States
IPO / Went publicBiocept is a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and biomarker analysis, headquartered in San Diego, California. The company's mission is to improve outcomes for cancer patients by advancing oncology diagnostics. Biocept utilizes patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. Additionally...Show allLogin to see details
See all 6 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Compositions and methods for detecting rare sequence variants Nov 01, 2017 Application
Compositions and methods for detecting rare sequence variants Dec 11, 2014 Application